Karachi: GlaxoSmithKline Pakistan Limited has disclosed its financial results for the nine months ending September 30, 2025, revealing a notable increase in profit despite the absence of any declared dividends or bonus shares. According to a statement released following the Board of Directors’ meeting held on October 24, 2025, the company reported substantial growth in several key financial metrics.
The company’s revenue from contracts with customers reached approximately 44.49 billion rupees for the nine-month period, showing a modest increase from the 43.60 billion rupees reported during the same period in 2024. The cost of sales saw a decline to 28.57 billion rupees from 34.06 billion rupees, resulting in a gross profit of 15.92 billion rupees, up from 9.54 billion rupees in the previous year.
Operating profit for the nine months stood at 10.48 billion rupees, a significant rise from the 5.84 billion rupees recorded in the prior year. This increase was driven by a reduction in cost-related expenses and a stable revenue stream. Profit before income tax reached 10.26 billion rupees, up from 5.56 billion rupees, and profit after taxation was 6.23 billion rupees, compared to 3.58 billion rupees previously. The earnings per share increased to 19.57 rupees from 11.25 rupees.
The statement of financial position as of September 30, 2025, indicated total assets amounting to 51.05 billion rupees, an increase from 45.06 billion rupees at the end of December 2024. The company’s equity rose to 29.73 billion rupees from 28.28 billion rupees, while total liabilities increased to 21.31 billion rupees from 16.78 billion rupees.
Despite these positive financial indicators, the Board of Directors did not recommend any cash dividend, bonus shares, or right shares for the period. Additionally, no other corporate actions or price-sensitive information were reported.
According to information available from the Pakistan Stock Exchange (PSX), the company’s financial outcome represents a robust performance, with a significant move in profitability metrics. Operating expenses, including selling, marketing, and distribution costs, increased to 3.89 billion rupees from 3.23 billion rupees, while administrative expenses rose to 1.55 billion rupees from 1.39 billion rupees.
GlaxoSmithKline Pakistan’s cash flow statement highlighted a net increase in cash and cash equivalents by 493.85 million rupees, bringing the total to 7.01 billion rupees at the end of the period. Cash generated from operations amounted to 10.84 billion rupees, with net cash from operating activities reported at 6.38 billion rupees.
The overall financial performance for the nine months ending September 30, 2025, reflects a strong operational strategy, with the company navigating challenges effectively to achieve substantial growth in its earnings and net profit.